NovaBay Pharmaceuticals (NBY)

Executive Summary

NovaBay Pharmaceuticals is undergoing a transformative reverse merger to become Stablecoin Development Corporation (SDEV), pivoting from biopharmaceuticals to the stablecoin and digital financial infrastructure ecosystem. The company's primary asset is a significant holding in SKY tokens from the Sky Protocol, a major yield-bearing stablecoin issuer. This strategic shift positions NovaBay to capitalize on the growing demand for decentralized finance (DeFi) and yield-generating digital assets. However, the transition carries execution and regulatory risks, and the company's future valuation is heavily tied to the success and adoption of the Sky Protocol. Despite its small market cap and historical losses, the pivot offers a speculative upside if the stablecoin market expands. The management team's ability to navigate the merger and integrate with the crypto ecosystem will be critical.

Upcoming Catalysts (preview)

• Q2 2026Completion of reverse merger into Stablecoin Development Corporation (SDEV)70% success
• TBDUpswing in Sky Protocol adoption or SKY token price appreciation40% success